Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
Maurie
M
Markman
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab; D018394:CA-125 Antigen / Q000097:blood*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000097:blood* / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D011859:Radiography; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018394:CA-125 Antigen; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab